

Gerhard Walzl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8371838/publications.pdf>

Version: 2024-02-01

246
papers

14,025
citations

19657

61
h-index

30087

103
g-index

260
all docs

260
docs citations

260
times ranked

12945
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results. <i>Clinical Infectious Diseases</i> , 2022, 74, 2136-2141.	5.8	46
2	Concurrent evaluation of cytokines improves the accuracy of antibodies against Mycobacterium tuberculosis antigens in the diagnosis of active tuberculosis. <i>Tuberculosis</i> , 2022, 133, 102169.	1.9	6
3	Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL): A cross-sectional observational study protocol using respondent driven sampling. <i>PLoS ONE</i> , 2022, 17, e0262440.	2.5	1
4	Immunometabolism of Myeloid-Derived Suppressor Cells: Implications for Mycobacterium tuberculosis Infection and Insights from Tumor Biology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3512.	4.1	3
5	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. <i>EBioMedicine</i> , 2022, 77, 103886.	6.1	2
6	Targeted Gene Expression Profiling of Human Myeloid Cells From Blood and Lung Compartments of Patients With Tuberculosis and Other Lung Diseases. <i>Frontiers in Immunology</i> , 2022, 13, 839747.	4.8	4
7	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. <i>Communications Medicine</i> , 2022, 2, .	4.2	15
8	Clinical predictors of pulmonary tuberculosis among South African adults with HIV. <i>EClinicalMedicine</i> , 2022, 45, 101328.	7.1	7
9	Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts. <i>BMC Infectious Diseases</i> , 2022, 22, 327.	2.9	7
10	Validation of host cerebrospinal fluid protein biomarkers for early diagnosis of tuberculous meningitis in children: a replication and new biosignature discovery study. <i>Biomarkers</i> , 2022, 27, 549-561.	1.9	1
11	Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. <i>EClinicalMedicine</i> , 2022, 47, 101396.	7.1	3
12	Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial. <i>EClinicalMedicine</i> , 2022, 48, 101414.	7.1	47
13	Localization of EccA3 at the growing pole in Mycobacterium smegmatis. <i>BMC Microbiology</i> , 2022, 22, 140.	3.3	1
14	Evaluation of host biomarkers for monitoring treatment response in spinal tuberculosis: A 12-month cohort study. <i>Cytokine</i> , 2022, 157, 155944.	3.2	2
15	Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1472-1483.	9.1	32
16	Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment. <i>EBioMedicine</i> , 2022, 82, 104173.	6.1	5
17	Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or Mycobacterium tuberculosis Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3398-e3408.	5.8	18
18	Evaluation of Potential Antigen-specific Host Biomarkers in QuantiFERON Supernatants as Candidates for the Diagnosis of Ocular Tuberculosis. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1480-1488.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors. <i>Journal of Leukocyte Biology</i> , 2021, 110, 177-186.	3.3	13
20	Impact of Intermediate Hyperglycemia and Diabetes on Immune Dysfunction in Tuberculosis. <i>Clinical Infectious Diseases</i> , 2021, 72, 69-78.	5.8	26
21	Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 2010-2021.	1.9	11
22	Tuberculous Meningitis: Pathogenesis, Immune Responses, Diagnostic Challenges, and the Potential of Biomarker-Based Approaches. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	29
23	Screening diabetes mellitus patients for pulmonary tuberculosis: a multisite study in Indonesia, Peru, Romania and South Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 634-643.	1.8	5
24	Identification of Potential Biomarkers in Peripheral Blood Supernatants of South African Patients with Syphilitic and Herpetic Uveitis. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 299-307.	1.8	4
25	A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries. <i>Frontiers in Immunology</i> , 2021, 12, 608846.	4.8	21
26	T cell-tropic HIV efficiently infects alveolar macrophages through contact with infected CD4+T cells. <i>Scientific Reports</i> , 2021, 11, 3890.	3.3	19
27	Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young Adults. <i>Frontiers in Immunology</i> , 2021, 12, 639965.	4.8	7
28	Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. <i>PLoS ONE</i> , 2021, 16, e0247852.	2.5	45
29	Validation and Optimization of Host Immunological Bio-Signatures for a Point-of-Care Test for TB Disease. <i>Frontiers in Immunology</i> , 2021, 12, 607827.	4.8	22
30	Evaluation of Host Serum Protein Biomarkers of Tuberculosis in sub-Saharan Africa. <i>Frontiers in Immunology</i> , 2021, 12, 639174.	4.8	21
31	Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	25
32	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 354-365.	9.1	84
33	Has the bubble burst for transcriptomics in tuberculosis diagnosis?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 301-302.	9.1	1
34	Visualizing the dynamics of tuberculosis pathology using molecular imaging. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	12
35	Serum and cerebrospinal fluid host proteins indicate stroke in children with tuberculous meningitis. <i>PLoS ONE</i> , 2021, 16, e0250944.	2.5	4
36	Safety and immunogenicity of the adjunct therapeutic vaccine ID93+GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 373-386.	10.7	46

#	ARTICLE	IF	CITATIONS
37	Chronological Metabolic Response to Intensive Phase TB Therapy in Patients with Cured and Failed Treatment Outcomes. <i>ACS Infectious Diseases</i> , 2021, 7, 1859-1869.	3.8	4
38	<i>Mycobacterium tuberculosis</i> -stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response. <i>Tuberculosis</i> , 2021, 128, 102082.	1.9	4
39	Dysregulation of the Immune Environment in the Airways During HIV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 707355.	4.8	6
40	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. <i>The Lancet Global Health</i> , 2021, 9, e841-e853.	6.3	34
41	Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis. <i>Cellular Immunology</i> , 2021, 364, 104359.	3.0	11
42	Biomarkers to predict FDG PET/CT activity after the standard duration of treatment for spinal tuberculosis: An exploratory study. <i>Tuberculosis</i> , 2021, 129, 102107.	1.9	2
43	Identification of novel salivary candidate protein biomarkers for tuberculosis diagnosis: A preliminary biomarker discovery study. <i>Tuberculosis</i> , 2021, 130, 102118.	1.9	5
44	Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1463-1472.	5.6	15
45	Inhaled particulate matter affects immune responsiveness of human lung phagocytes to mycobacteria. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L566-L575.	2.9	1
46	Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis. <i>Lancet Microbe</i> , The, 2021, 2, e518-e526.	7.3	16
47	CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries. <i>Journal of Infection</i> , 2021, 83, 433-443.	3.3	4
48	Evaluation of autophagy mediators in myeloid-derived suppressor cells during human tuberculosis. <i>Cellular Immunology</i> , 2021, 369, 104426.	3.0	7
49	Candidate Biomarkers to Distinguish Spinal Tuberculosis From Mechanical Back Pain in a Tuberculosis Endemic Setting. <i>Frontiers in Immunology</i> , 2021, 12, 768040.	4.8	8
50	Diabetes Mellitus Among Pulmonary Tuberculosis Patients From 4 Tuberculosis-endemic Countries: The TANDEM Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 780-788.	5.8	57
51	The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 1497-1509.	5.4	48
52	An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with <i>M. tuberculosis</i> specific antibodies in Cape Town, South Africa. <i>EBioMedicine</i> , 2020, 61, 103053.	6.1	22
53	GPR183 Regulates Interferons, Autophagy, and Bacterial Growth During <i>Mycobacterium tuberculosis</i> Infection and Is Associated With TB Disease Severity. <i>Frontiers in Immunology</i> , 2020, 11, 601534.	4.8	25
54	Investigating Non-sterilizing Cure in TB Patients at the End of Successful Anti-TB Therapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 443.	3.9	21

#	ARTICLE	IF	CITATIONS
55	Host urine immunological biomarkers as potential candidates for the diagnosis of tuberculosis. <i>International Journal of Infectious Diseases</i> , 2020, 99, 473-481.	3.3	16
56	Biosignatures: The answer to Tuberculosis diagnosis in children?. <i>EBioMedicine</i> , 2020, 60, 102977.	6.1	1
57	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. <i>Molecular Immunology</i> , 2020, 120, 187-195.	2.2	19
58	Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis. <i>Frontiers in Immunology</i> , 2020, 11, 451.	4.8	18
59	<i>Mycobacterium tuberculosis</i> and myeloid-derived suppressor cells: Insights into caveolin rich lipid rafts. <i>EBioMedicine</i> , 2020, 53, 102670.	6.1	17
60	The Peripheral Blood Transcriptome Is Correlated With PET Measures of Lung Inflammation During Successful Tuberculosis Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 596173.	4.8	6
61	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. <i>Scientific Reports</i> , 2020, 10, 8629.	3.3	90
62	S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 3098-3112.	8.2	85
63	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. <i>Journal of Clinical Investigation</i> , 2020, 130, 2789-2799.	8.2	26
64	Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response. <i>EJNMMI Research</i> , 2020, 10, 8.	2.5	27
65	Distinct serum biosignatures are associated with different tuberculosis treatment outcomes. <i>Tuberculosis</i> , 2019, 118, 101859.	1.9	24
66	Prospective evaluation of host biomarkers other than interferon gamma in QuantiFERON Plus supernatants as candidates for the diagnosis of tuberculosis in symptomatic individuals. <i>Journal of Infection</i> , 2019, 79, 228-235.	3.3	24
67	Potential of Host Serum Protein Biomarkers in the Diagnosis of Tuberculous Meningitis in Children. <i>Frontiers in Pediatrics</i> , 2019, 7, 376.	1.9	24
68	Diagnostic Accuracy of Early Secretory Antigenic Target-6-Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube. <i>Clinical Infectious Diseases</i> , 2019, 69, 1724-1730.	5.8	12
69	Application of Cerebrospinal Fluid Host Protein Biosignatures in the Diagnosis of Tuberculous Meningitis in Children from a High Burden Setting. <i>Mediators of Inflammation</i> , 2019, 2019, 1-11.	3.0	24
70	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2019, 10, 1441.	3.5	46
71	Oxidized low-density lipoprotein (oxLDL) supports <i>Mycobacterium tuberculosis</i> survival in macrophages by inducing lysosomal dysfunction. <i>PLoS Pathogens</i> , 2019, 15, e1007724.	4.7	32
72	Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002781.	8.4	72

#	ARTICLE	IF	CITATIONS
73	Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. <i>Frontiers in Immunology</i> , 2019, 10, 527.	4.8	40
74	The level of the endoplasmic reticulum stress chaperone protein, binding immunoglobulin protein (BiP), decreases following successful tuberculosis treatment. <i>International Journal of Infectious Diseases</i> , 2019, 81, 198-202.	3.3	6
75	The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda. <i>Lancet Respiratory Medicine</i> , 2019, 7, 892-906.	10.7	62
76	Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis. <i>Journal of Infectious Diseases</i> , 2019, 220, S108-S115.	4.0	38
77	Caveolin-1 Controls Vesicular TLR2 Expression, p38 Signaling and T Cell Suppression in BCG Infected Murine Monocytic Myeloid-Derived Suppressor Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2826.	4.8	18
78	Time-Dependent Changes in Urinary Metabolome Before and After Intensive Phase Tuberculosis Therapy: A Pharmacometabolomics Study. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 560-572.	2.0	17
79	Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy. <i>ACS Infectious Diseases</i> , 2019, 5, 353-364.	3.8	9
80	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 564-571.	5.6	20
81	Heat-killed <i>Mycobacterium tuberculosis</i> prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell killing capability. <i>JCI Insight</i> , 2019, 4, .	5.0	23
82	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1198-1208.	5.6	217
83	Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis. <i>Scientific Reports</i> , 2018, 8, 2675.	3.3	44
84	Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. <i>Lancet Infectious Diseases</i> , 2018, 18, e183-e198.	9.1	281
85	Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. <i>Lancet Infectious Diseases</i> , 2018, 18, e199-e210.	9.1	244
86	Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. <i>Bulletin of the World Health Organization</i> , 2018, 96, 738-749.	3.3	19
87	A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images. <i>EJNMMI Research</i> , 2018, 8, 55.	2.5	16
88	Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2018, 66, 554-563.	5.8	32
89	Metabolite changes in blood predict the onset of tuberculosis. <i>Nature Communications</i> , 2018, 9, 5208.	12.8	129
90	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 2427.	4.8	43

#	ARTICLE	IF	CITATIONS
91	Antibody and Host Inflammatory Biomarker Combinations as Diagnostic Tools for TB Disease. <i>American Journal of Clinical Pathology</i> , 2018, 150, S126-S127.	0.7	0
92	Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response. <i>JAMA Network Open</i> , 2018, 1, e183779.	5.9	96
93	Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 332.	3.9	22
94	Human Monocytic Suppressive Cells Promote Replication of <i>Mycobacterium tuberculosis</i> and Alter Stability of in vitro Generated Granulomas. <i>Frontiers in Immunology</i> , 2018, 9, 2417.	4.8	32
95	PD-1 Expression on <i>Mycobacterium tuberculosis</i> -Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 1995.	4.8	68
96	Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile. <i>EBioMedicine</i> , 2018, 32, 192-200.	6.1	36
97	Diagnostic Challenge of Tuberculosis Heterogeneity. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 286-296.	2.1	1
98	A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts. <i>Frontiers in Immunology</i> , 2018, 9, 661.	4.8	42
99	Diabetes screen during tuberculosis contact investigations highlights opportunity for new diabetes diagnosis and reveals metabolic differences between ethnic groups. <i>Tuberculosis</i> , 2018, 113, 10-18.	1.9	16
100	Disease characteristics and treatment of patients with diabetes mellitus attending government health services in Indonesia, Peru, Romania and South Africa. <i>Tropical Medicine and International Health</i> , 2018, 23, 1118-1128.	2.3	15
101	A multi-cohort study of the immune factors associated with <i>M. tuberculosis</i> infection outcomes. <i>Nature</i> , 2018, 560, 644-648.	27.8	184
102	The potential of imaging tools as correlates of infection and disease for new TB vaccine development. <i>Seminars in Immunology</i> , 2018, 39, 73-80.	5.6	7
103	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. <i>Tuberculosis</i> , 2018, 109, 61-68.	1.9	28
104	POLICY-DRIVEN INTERVENTIONS: TUBERCULOSIS. <i>BMJ Global Health</i> , 2017, 2, A4.1-A4.	4.7	0
105	B α cells with a FasL expressing regulatory phenotype are induced following successful anti-tuberculosis treatment. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 57-67.	2.7	16
106	High-throughput Identification of DNA-Encoded IgG Ligands that Distinguish Active and Latent <i>Mycobacterium tuberculosis</i> Infections. <i>ACS Chemical Biology</i> , 2017, 12, 234-243.	3.4	55
107	Re. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 241-242.	2.0	0
108	Cardiovascular risk and endothelial function in people living with HIV/AIDS: design of the multi-site, longitudinal EndoAfrica study in the Western Cape Province of South Africa. <i>BMC Infectious Diseases</i> , 2017, 17, 41.	2.9	28

#	ARTICLE	IF	CITATIONS
109	Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. <i>Vaccine Journal</i> , 2017, 24, .	3.1	112
110	Urinary metabolite markers characterizing tuberculosis treatment failure. <i>Metabolomics</i> , 2017, 13, 1.	3.0	23
111	Host blood RNA signatures predict the outcome of tuberculosis treatment. <i>Tuberculosis</i> , 2017, 107, 48-58.	1.9	156
112	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of <i>Mycobacterium tuberculosis</i> Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 638-648.	5.6	124
113	Predicting tuberculosis treatment outcome using metabolomics. <i>Biomarkers in Medicine</i> , 2017, 11, 1057-1067.	1.4	16
114	Phenotypically resembling myeloid derived suppressor cells are increased in children with HIV and exposed/infected with <i>Mycobacterium tuberculosis</i> . <i>European Journal of Immunology</i> , 2017, 47, 107-118.	2.9	27
115	Detection of a combination of serum IgG and IgA antibodies against selected mycobacterial targets provides promising diagnostic signatures for active TB. <i>Oncotarget</i> , 2017, 8, 37525-37537.	1.8	21
116	Changes in Host Immune-Endocrine Relationships during Tuberculosis Treatment in Patients with Cured and Failed Treatment Outcomes. <i>Frontiers in Immunology</i> , 2017, 8, 690.	4.8	7
117	Suitability of saliva for Tuberculosis diagnosis: comparing with serum. <i>BMC Infectious Diseases</i> , 2017, 17, 600.	2.9	21
118	Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. <i>Gates Open Research</i> , 2017, 1, 9.	1.1	22
119	Successful TB treatment induces B-cells expressing FASL and IL5RA mRNA. <i>Oncotarget</i> , 2017, 8, 2037-2043.	1.8	21
120	Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response. <i>Oncotarget</i> , 2016, 7, 57581-57592.	1.8	81
121	Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB. <i>PLoS ONE</i> , 2016, 11, e0160062.	2.5	35
122	Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease. <i>Journal of Infection</i> , 2016, 73, 219-230.	3.3	28
123	The Effect of Deworming on Tests of Tuberculosis Infection in Children With Recent Tuberculosis Exposure. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 622-627.	2.0	13
124	Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. <i>Thorax</i> , 2016, 71, 785-794.	5.6	134
125	Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. <i>Nature Medicine</i> , 2016, 22, 1090-1093.	30.7	166
126	Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. <i>Nature Medicine</i> , 2016, 22, 1094-1100.	30.7	247

#	ARTICLE	IF	CITATIONS
127	Sputum is a surrogate for bronchoalveolar lavage for monitoring Mycobacterium tuberculosis transcriptional profiles in TB patients. Tuberculosis, 2016, 100, 89-94.	1.9	27
128	Phenotypic analysis of peripheral B cell populations during Mycobacterium tuberculosis infection and disease. Journal of Inflammation, 2016, 13, 23.	3.4	25
129	Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy. BMC Medicine, 2016, 14, 68.	5.5	55
130	B cells as multi-functional players during Mycobacterium tuberculosis infection and disease. Tuberculosis, 2016, 97, 118-125.	1.9	16
131	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, The, 2016, 387, 2312-2322.	13.7	678
132	Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment. Cytokine, 2016, 81, 50-56.	3.2	56
133	Use of lateral flow assays to determine IP-10 and CCL4 levels in pleural effusions and whole blood for TB diagnosis. Tuberculosis, 2016, 96, 31-36.	1.9	33
134	Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. Clinical Biochemistry, 2016, 49, 22-31.	1.9	49
135	QuantIFERON-TB performance enhanced by novel Mycobacterium tuberculosis-specific antigens. European Respiratory Journal, 2016, 47, 660-664.	6.7	9
136	Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment. Journal of Infectious Diseases, 2016, 213, 485-495.	4.0	34
137	The Functional Response of B Cells to Antigenic Stimulation: A Preliminary Report of Latent Tuberculosis. PLoS ONE, 2016, 11, e0152710.	2.5	24
138	Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response. PLoS ONE, 2016, 11, e0160546.	2.5	45
139	A Subgroup of LatentlyMycobacterium tuberculosisInfected Individuals Is Characterized by Consistently Elevated IgA Responses to Several Mycobacterial Antigens. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	18
140	Acquired immunodeficiencies and tuberculosis: focus on <scp>HIV</scp></><scp>AIDS</scp> and diabetes mellitus. Immunological Reviews, 2015, 264, 121-137.	6.0	87
141	Optimizing the Detection of Recent Tuberculosis Infection in Children in a High Tuberculosisâ€“HIV Burden Setting. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 820-830.	5.6	46
142	Frequency of Mycobacterium tuberculosis-specific CD8+ T-cells in the course of anti-tuberculosis treatment. International Journal of Infectious Diseases, 2015, 32, 23-29.	3.3	20
143	Genital Inflammation and the Risk of HIV Acquisition in Women. Clinical Infectious Diseases, 2015, 61, 260-269.	5.8	354
144	A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis: Table 1.. Clinical Infectious Diseases, 2015, 61, S164-S172.	5.8	26

#	ARTICLE	IF	CITATIONS
145	Evaluation of a radiological severity score to predict treatment outcome in adults with pulmonary tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1354-1360.	1.2	20
146	Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 454-462.	1.2	22
147	Epigenetics and Proteomics Join Transcriptomics in the Quest for Tuberculosis Biomarkers. <i>MBio</i> , 2015, 6, e01187-15.	4.1	70
148	Clinical Immunology and Multiplex Biomarkers of Human Tuberculosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a018515-a018515.	6.2	32
149	Host Immune Response to Tuberculous Meningitis. <i>Clinical Infectious Diseases</i> , 2015, 60, 177-187.	5.8	52
150	Host Cytokine Responses Induced after Overnight Stimulation with Novel M. tuberculosis Infection Phase-Dependent Antigens Show Promise as Diagnostic Candidates for TB Disease. <i>PLoS ONE</i> , 2014, 9, e102584.	2.5	30
151	The BCG replacement vaccine VPM1002: from drawing board to clinical trial. <i>Expert Review of Vaccines</i> , 2014, 13, 619-630.	4.4	62
152	Bifunctional T-Cell-Derived Cytokines for the Diagnosis of Tuberculosis and Treatment Monitoring. <i>Respiration</i> , 2014, 88, 251-261.	2.6	16
153	Proliferative capacity and cytokine production by cells of HIV-infected and uninfected adults with different helminth infection phenotypes in South Africa. <i>BMC Infectious Diseases</i> , 2014, 14, 499.	2.9	8
154	A metabolic biosignature of early response to anti-tuberculosis treatment. <i>BMC Infectious Diseases</i> , 2014, 14, 53.	2.9	64
155	<i>Mycobacterium bovis</i> BCG infection severely delays <i>Trichuris muris</i> expulsion and co-infection suppresses immune responsiveness to both pathogens. <i>BMC Microbiology</i> , 2014, 14, 9.	3.3	13
156	Distinct Cytokine Patterns in Semen Influence Local HIV Shedding and HIV Target Cell Activation. <i>Journal of Infectious Diseases</i> , 2014, 209, 1174-1184.	4.0	42
157	Serologic diagnosis of tuberculosis by combining Ig classes against selected mycobacterial targets. <i>Journal of Infection</i> , 2014, 69, 581-589.	3.3	45
158	Differential gene expression of activating Fc γ 3 receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. <i>Clinical Microbiology and Infection</i> , 2014, 20, O230-O238.	6.0	65
159	Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. <i>Sexually Transmitted Infections</i> , 2014, 90, 580-587.	1.9	173
160	Rapid diagnosis of tuberculosis using ex vivo host biomarkers in sputum. <i>European Respiratory Journal</i> , 2014, 44, 254-257.	6.7	20
161	Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients. <i>BMC Infectious Diseases</i> , 2014, 14, 125.	2.9	30
162	Combination of gene expression patterns in whole blood discriminate between tuberculosis infection states. <i>BMC Infectious Diseases</i> , 2014, 14, 257.	2.9	30

#	ARTICLE	IF	CITATIONS
163	Beyond the IFN- γ horizon: biomarkers for immunodiagnosis of infection with <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2014, 43, 1472-1486.	6.7	135
164	Helminth-M. Tb Co-Infection. <i>Advances in Experimental Medicine and Biology</i> , 2014, 828, 49-74.	1.6	13
165	Increased Frequency of Myeloid-derived Suppressor Cells during Active Tuberculosis and after Recent <i>Mycobacterium tuberculosis</i> Infection Suppresses T-Cell Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 724-732.	5.6	149
166	Acute helminth infection enhances early macrophage mediated control of mycobacterial infection. <i>Mucosal Immunology</i> , 2013, 6, 931-941.	6.0	41
167	Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. <i>Journal of Infection</i> , 2013, 66, 357-365.	3.3	95
168	Serodiagnostic markers for the prediction of the outcome of intensive phase tuberculosis therapy. <i>Tuberculosis</i> , 2013, 93, 239-245.	1.9	19
169	BDNF Val66Met and DRD2 Taq1A polymorphisms interact to influence PTSD symptom severity: A preliminary investigation in a South African population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 40, 273-280.	4.8	34
170	Differential Expression of Host Biomarkers in Saliva and Serum Samples from Individuals with Suspected Pulmonary Tuberculosis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	3.0	47
171	Exploring Alternative Biomaterials for Diagnosis of Pulmonary Tuberculosis in HIV-Negative Patients by Use of the GeneXpert MTB/RIF Assay. <i>Journal of Clinical Microbiology</i> , 2013, 51, 4161-4166.	3.9	42
172	Distinct Phases of Blood Gene Expression Pattern Through Tuberculosis Treatment Reflect Modulation of the Humoral Immune Response. <i>Journal of Infectious Diseases</i> , 2013, 207, 18-29.	4.0	218
173	The Contraceptive Depot Medroxyprogesterone Acetate Impairs Mycobacterial Control and Inhibits Cytokine Secretion in Mice Infected with <i>Mycobacterium tuberculosis</i> . <i>Infection and Immunity</i> , 2013, 81, 1234-1244.	2.2	28
174	Detecting Tuberculosis Infection in HIV-infected Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e111-e118.	2.0	44
175	A Broad Profile of Co-Dominant Epitopes Shapes the Peripheral <i>Mycobacterium tuberculosis</i> Specific CD8+ T-Cell Immune Response in South African Patients with Active Tuberculosis. <i>PLoS ONE</i> , 2013, 8, e58309.	2.5	27
176	Decreased Expression of miR-21, miR-26a, miR-29a, and miR-142-3p in CD4+ T Cells and Peripheral Blood from Tuberculosis Patients. <i>PLoS ONE</i> , 2013, 8, e61609.	2.5	73
177	Analysis of Host Responses to <i>Mycobacterium tuberculosis</i> Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa. <i>PLoS ONE</i> , 2013, 8, e74080.	2.5	48
178	Modern lineages of <i>Mycobacterium tuberculosis</i> in Addis Ababa, Ethiopia: implications for the tuberculosis control programme. <i>African Health Sciences</i> , 2013, 12, 339-44.	0.7	19
179	Utility of Host Markers Detected in Quantiferon Supernatants for the Diagnosis of Tuberculosis in Children in a High-Burden Setting. <i>PLoS ONE</i> , 2013, 8, e64226.	2.5	61
180	Biomarkers of Inflammation, Immunosuppression and Stress Are Revealed by Metabolomic Profiling of Tuberculosis Patients. <i>PLoS ONE</i> , 2012, 7, e40221.	2.5	195

#	ARTICLE	IF	CITATIONS
181	Heparin-Binding Hemagglutinin Induces IFN- γ IL-2 IL-17 Multifunctional CD4 ⁺ T Cells during Latent but Not Active Tuberculosis Disease. <i>Vaccine Journal</i> , 2012, 19, 746-751.	3.1	26
182	Genital Tract Inflammation During Early HIV-1 Infection Predicts Higher Plasma Viral Load Set Point in Women. <i>Journal of Infectious Diseases</i> , 2012, 205, 194-203.	4.0	67
183	Symptomatic Vaginal Discharge Is a Poor Predictor of Sexually Transmitted Infections and Genital Tract Inflammation in High-Risk Women in South Africa. <i>Journal of Infectious Diseases</i> , 2012, 206, 6-14.	4.0	171
184	Plasma Level of IL-4 Differs in Patients Infected with Different Modern Lineages of <i>M. tuberculosis</i> . <i>Journal of Tropical Medicine</i> , 2012, 2012, 1-6.	1.7	11
185	Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 1033-1039.	1.2	78
186	Development of a diagnostic gene expression assay for tuberculosis and its use under field conditions in African buffaloes (<i>Syncerus caffer</i>). <i>Veterinary Immunology and Immunopathology</i> , 2012, 148, 337-342.	1.2	12
187	Detection and treatment of subclinical tuberculosis. <i>Tuberculosis</i> , 2012, 92, 447-452.	1.9	33
188	Effect of <i>Ascaris Lumbricoides</i> specific IgE on tuberculin skin test responses in children in a high-burden setting: a cross-sectional community-based study. <i>BMC Infectious Diseases</i> , 2012, 12, 211.	2.9	28
189	Baseline Predictors of Sputum Culture Conversion in Pulmonary Tuberculosis: Importance of Cavities, Smoking, Time to Detection and W-Beijing Genotype. <i>PLoS ONE</i> , 2012, 7, e29588.	2.5	52
190	Effect of Standard Tuberculosis Treatment on Plasma Cytokine Levels in Patients with Active Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2012, 7, e36886.	2.5	81
191	Potential of novel <i>Mycobacterium tuberculosis</i> infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. <i>BMC Infectious Diseases</i> , 2012, 12, 10.	2.9	63
192	Potential of Host Markers Produced by Infection Phase-Dependent Antigen-Stimulated Cells for the Diagnosis of Tuberculosis in a Highly Endemic Area. <i>PLoS ONE</i> , 2012, 7, e38501.	2.5	50
193	Tuberculosis assays: past, present and future. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 457-469.	4.4	56
194	Suppressor of cytokine signaling-3 is affected in T-cells from tuberculosis TB patients. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1323-1331.	6.0	44
195	Immunological biomarkers of tuberculosis. <i>Nature Reviews Immunology</i> , 2011, 11, 343-354.	22.7	455
196	Human gene expression profiles of susceptibility and resistance in tuberculosis. <i>Genes and Immunity</i> , 2011, 12, 15-22.	4.1	288
197	Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. <i>Tuberculosis</i> , 2011, 91, 587-593.	1.9	71
198	The influence of different helminth infection phenotypes on immune responses against HIV in co-infected adults in South Africa. <i>BMC Infectious Diseases</i> , 2011, 11, 273.	2.9	42

#	ARTICLE	IF	CITATIONS
199	Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. <i>European Respiratory Journal</i> , 2011, 37, 1248-1259.	6.7	130
200	Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum <i>Mycobacterium tuberculosis</i> Bacillary Load during Treatment. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3905-3911.	3.9	97
201	The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2011, 93, 93-100.	4.7	56
202	Medroxyprogesterone Acetate Alters <i>Mycobacterium Bovis</i> BCG-Induced Cytokine Production in Peripheral Blood Mononuclear Cells of Contraceptive Users. <i>PLoS ONE</i> , 2011, 6, e24639.	2.5	30
203	Cytokines in Pulmonary Tuberculosis. , 2011, , 123-137.		0
204	Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. <i>Aids</i> , 2010, 24, 819-831.	2.2	195
205	Challenges and perspectives for improved management of HIV/ <i>Mycobacterium tuberculosis</i> co-infection. <i>European Respiratory Journal</i> , 2010, 36, 1242-1247.	6.7	39
206	Biomarker discovery in heterogeneous tissue samples -taking the in-silico deconfounding approach. <i>BMC Bioinformatics</i> , 2010, 11, 27.	2.6	95
207	Direct comparison of the diagnostic yield of ultrasound-assisted Abrams and Tru-Cut needle biopsies for pleural tuberculosis. <i>Thorax</i> , 2010, 65, 857-862.	5.6	103
208	Higher human CD4 T cell response to novel <i>Mycobacterium tuberculosis</i> latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. <i>Vaccine</i> , 2010, 29, 51-57.	3.8	64
209	Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. <i>Lancet, The</i> , 2010, 375, 1920-1937.	13.7	404
210	Highly discordant T cell responses in individuals with recent exposure to household tuberculosis. <i>Thorax</i> , 2009, 64, 840-846.	5.6	71
211	Short-Term Reproducibility of a Commercial Interferon Gamma Release Assay. <i>Vaccine Journal</i> , 2009, 16, 1170-1175.	3.1	66
212	Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of <i>Mycobacterium tuberculosis</i> in Three High-Burden Populations in Africa. <i>Vaccine Journal</i> , 2009, 16, 1203-1212.	3.1	148
213	Host markers in Quantiferon supernatants differentiate active TB from latent TB infection: preliminary report. <i>BMC Pulmonary Medicine</i> , 2009, 9, 21.	2.0	150
214	Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. <i>Clinical and Experimental Immunology</i> , 2009, 156, 69-77.	2.6	97
215	Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. <i>Cytokine</i> , 2009, 47, 132-136.	3.2	54
216	Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. <i>Vaccine</i> , 2009, 27, 5488-5495.	3.8	117

#	ARTICLE	IF	CITATIONS
217	Pleural Tuberculosis in Patients with Early HIV Infection Is Associated with Increased TNF-Alpha Expression and Necrosis in Granulomas. PLoS ONE, 2009, 4, e4228.	2.5	37
218	Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. Journal of Infection, 2008, 56, 340-347.	3.3	62
219	Biomarkers for TB treatment response: Challenges and future strategies. Journal of Infection, 2008, 57, 103-109.	3.3	57
220	High levels of intracellular IL-4 are expressed in circulating apoptotic T cells in patients with tuberculosis and in community controls. Tuberculosis, 2008, 88, 21-30.	1.9	9
221	Evaluation of Adapted Whole-Blood Interferon- γ ; Release Assays for the Diagnosis of Pleural Tuberculosis. Respiration, 2008, 76, 131-138.	2.6	66
222	Differential Expression of Interleukin-4 (IL-4) and IL-4 ^{hi} mRNA, but Not Transforming Growth Factor Beta (TGF- β 2), TGF- β 2RII, Foxp3, Gamma Interferon, T-bet, or GATA-3 mRNA, in Patients with Fast and Slow Responses to Antituberculosis Treatment. Vaccine Journal, 2008, 15, 1165-1170.	3.1	35
223	Distinct, Specific IL-17- and IL-22-Producing CD4+ T Cell Subsets Contribute to the Human Anti-Mycobacterial Immune Response. Journal of Immunology, 2008, 180, 1962-1970.	0.8	378
224	An Evaluation of Commercial Fluorescent Bead-Based Luminex Cytokine Assays. PLoS ONE, 2008, 3, e2535.	2.5	137
225	Immunosuppression during Active Tuberculosis Is Characterized by Decreased Interferon- γ Production and CD25 Expression with Elevated Forkhead Box P3, Transforming Growth Factor- β 2, and Interleukin-4 mRNA Levels. Journal of Infectious Diseases, 2007, 195, 870-878.	4.0	113
226	Reply to Davies et al.. Journal of Infectious Diseases, 2007, 196, 649-650.	4.0	1
227	Changes in the kinetics of intracellular IFN- γ production in TB patients during treatment. Clinical Immunology, 2007, 124, 336-344.	3.2	27
228	Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis patients. Tuberculosis, 2007, 87, 295-302.	1.9	80
229	Correlates for disease progression and prognosis during concurrent HIV/TB infection. International Journal of Infectious Diseases, 2007, 11, 289-299.	3.3	58
230	Antimicrobial resistance in tuberculosis: an international perspective. Expert Review of Anti-Infective Therapy, 2006, 4, 759-766.	4.4	19
231	Recall of intestinal helminthiasis by HIV-infected South Africans and avoidance of possible misinterpretation of egg excretion in worm/HIV co-infection analyses. BMC Infectious Diseases, 2006, 6, 88.	2.9	17
232	Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clinical and Experimental Immunology, 2006, 145, 252-260.	2.6	62
233	Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clinical and Experimental Immunology, 2006, 146, 243-252.	2.6	68
234	Role of CCL5 (RANTES) in Viral Lung Disease. Journal of Virology, 2006, 80, 8151-8157.	3.4	106

#	ARTICLE	IF	CITATIONS
235	TB: a partnership for the benefit of research and community. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 15-19.	1.8	10
236	OX40 Ligation on Activated T Cells Enhances the Control of <i>Cryptococcus neoformans</i> and Reduces Pulmonary Eosinophilia. Journal of Immunology, 2003, 170, 6125-6132.	0.8	46
237	A Critical Role for OX40 in T Cell-mediated Immunopathology during Lung Viral Infection. Journal of Experimental Medicine, 2003, 198, 1237-1242.	8.5	103
238	Prior Exposure to Live Mycobacterium bovis BCG Decreases Cryptococcus neoformans -Induced Lung Eosinophilia in a Gamma Interferon-Dependent Manner. Infection and Immunity, 2003, 71, 3384-3391.	2.2	24
239	Modulation of Immune Responses to Virus Infection in the Lung. , 2003, , .		0
240	Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nature Medicine, 2001, 7, 732-737.	30.7	134
241	Inhibition of T1/St2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 (Th2)- but Not Th1-Driven Immunopathology. Journal of Experimental Medicine, 2001, 193, 785-792.	8.5	104
242	Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses. Journal of Immunology, 2001, 166, 1106-1113.	0.8	94
243	Influenza Virus Lung Infection Protects from Respiratory Syncytial Virus-induced Immunopathology. Journal of Experimental Medicine, 2000, 192, 1317-1326.	8.5	127
244	Corticosteroids in the Treatment of Tuberculous Pleurisy. Chest, 1996, 110, 333-338.	0.8	116
245	TB Epidemiology and Human Genetics. Novartis Foundation Symposium, 0, , 17-41.	1.1	11
246	Predicting TB treatment outcomes using baseline risk and treatment response markers: developing the PredictTB early treatment completion criteria. Gates Open Research, 0, 4, 157.	1.1	0